| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5877192 | ASTRAZENECA | Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole |
May, 2014
(9 years ago) | |
| US6143771 | ASTRAZENECA | Compounds |
May, 2014
(9 years ago) | |
|
US5877192 (Pediatric) | ASTRAZENECA | Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole |
Nov, 2014
(9 years ago) | |
Nexium Iv is owned by Astrazeneca.
Nexium Iv contains Esomeprazole Sodium.
Nexium Iv has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Nexium Iv are:
- US5877192
- US6143771
- US5877192*PED
Nexium Iv was authorised for market use on 31 March, 2005.
Nexium Iv is available in injectable;intravenous dosage forms.
Nexium Iv can be used as the short term treatment (up to 10 days) in pts having gastroesophageal reflux disease (gerd) as an alternative to oral therapy in pts when therapy with nexium capsules is not possible or appropriate.
The generics of Nexium Iv are possible to be released after 04 March, 2017.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-138) | Mar 04, 2017 |
| New Indication(I-679) | Mar 04, 2017 |
Drugs and Companies using ESOMEPRAZOLE SODIUM ingredient
Market Authorisation Date: 31 March, 2005
Treatment: The short term treatment (up to 10 days) in pts having gastroesophageal reflux disease (gerd) as an alternative to oral therapy in pts when therapy with nexium capsules is not possible or appropriate
Dosage: INJECTABLE;INTRAVENOUS
NEXIUM IV family patents
